Market Overview

Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI 62.5/25mcg Dose for COPD

Share:
Related GSK
Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer
US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings
Premarket Biotech Digest: Pump-And-Dumps, MannKind DTC Campaign, Opdivo ODD (Seeking Alpha)
Related THRX
Short-Sellers Betting Against These Biotechs
Morning Market Losers

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25mcg dose) for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

ANORO(TM) ELLIPTA(TM) is the proposed proprietary name for UMEC/VI, a combination of two investigational bronchodilator molecules -- GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the ELLIPTA(TM) inhaler.

The FDA Advisory Committee also voted that the safety of the investigational medicine has been adequately demonstrated at the 62.5/25mcg dose for the proposed indication (10 yes, 3 no), and the efficacy data provided substantial evidence of a clinically meaningful benefit for UMEC/VI 62.5/25mcg once daily for the long-term, maintenance treatment of airflow obstruction in COPD (13 yes, 0 no).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Get Benzinga's Newsletters